Teva stock outlook strengthens as innovative brands expand

Teva Pharmaceutical Industries reported third-quarter results on November 3, 2026, highlighting faster growth in its innovative medicines portfolio and a higher outlook for several key brands. The company published the results in a Teva press release.

Innovative brands drive the pivot

Revenue for the quarter ended September 30, 2026, reached 4.395 billion US dollars, down 2 percent from a year earlier. Lower global generic-drug revenue, particularly from lenalidomide capsules in the United States, offset continued expansion in AUSTEDO, AJOVY and UZEDY.

The three innovative brands generated approximately 1.1 billion US dollars and grew 33 percent year over year in local currency. AUSTEDO revenue rose 21 percent to 751 million US dollars, AJOVY increased 61 percent to 269 million US dollars and UZEDY advanced 96 percent to 85 million US dollars.

Higher targets meet generic pressure

Teva lifted its 2026 revenue outlook to 16.7 billion to 17.0 billion US dollars from 16.5 billion to 16.85 billion US dollars previously. The company also raised its brand-specific targets: AUSTEDO to 2.55 billion to 2.65 billion US dollars, AJOVY to 930 million to 960 million US dollars and UZEDY to 290 million to 310 million US dollars.

GAAP diluted earnings per share were 0.20 US dollars, while non-GAAP diluted earnings per share reached 0.86 US dollars. Non-GAAP gross margin rose to 58.7 percent, supported by a more favorable product mix, although the company reported legal settlements, impairments and other non-GAAP adjustments in the quarter.

Pipeline adds future catalysts

Teva said the US launch of WELTRUZA, a once-monthly injectable treatment for schizophrenia, expands its neuroscience franchise. The company also highlighted its biosimilar collaboration with Samsung Bioepis and expects biosimilar revenue to exceed 0.8 billion US dollars in 2026.

The next scheduled corporate event is Teva's R&D Day in New York on November 11, 2026. For investors, the key issue is whether innovative-brand growth can offset generic competition and support the company's margin and cash-flow targets.